文献速递银屑病与炎症性皮肤病

银屑病关节炎与非关节炎银屑病患者表型、共病、治疗及不良事件比较:Biobadaderm登记研究

Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-04-12

基于Biobadaderm前瞻性起始队列,纳入2120例接受系统治疗的银屑病患者(无关节炎1871例,银屑病关节炎249例)。银屑病关节炎患者共病更多(尤其高血压和肝病),使用更多系统治疗(尤其抗TNFα药物和联合治疗),不良事件发生率更高(调整IRR=1.29,95%CI 1.05-1.58),尤其严重不良事件(调整IRR=1.51,95%CI 1.01-2.26)和感染/寄生虫感染(调整IRR=1.88,95%CI 1.27-2.79)。

要点

  • 银屑病关节炎患者共病负担更重,尤其高血压和肝病更常见。
  • 银屑病关节炎患者抗TNFα药物和联合治疗使用更多。
  • 银屑病关节炎患者不良事件风险更高,应更密切随访管理。

核心结论

  • 银屑病关节炎患者与单纯银屑病患者在表型、共病、治疗及不良事件方面存在差异,应更密切和针对性地随访管理。

研究设计与样本

  • 排除随访期间出现任何关节受累体征和/或症状的患者。

主要发现

  • 银屑病关节炎组共病更多,尤其高血压和肝病。
  • 银屑病关节炎组使用更多系统治疗,尤其抗TNFα药物和联合治疗。
  • 银屑病关节炎组不良事件调整IRR=1.29(95%CI 1.05-1.58),严重不良事件调整IRR=1.51(95%CI 1.01-2.26),感染/寄生虫感染调整IRR=1.88(95%CI 1.27-2.79),独立于相关共病和当前/既往治疗。

关键数值与推荐

  • 无关节炎组随访5020患者年,银屑病关节炎组随访762患者年。
  • 不良事件发生率比值(IRR)采用混合效应泊松回归估计。

临床怎么用

  • 对银屑病关节炎患者应更密切随访,特别关注严重不良事件和感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are a limited number of studies comparing psoriasis patients without psoriatic arthritis (PsA) to those with arthritis. Previous results are controversial. OBJECTIVES: To perform a comparative analysis of the phenotype, baseline comorbidities, therapeutic profile and incidence of adverse events (particularly overall adverse events, infections and infestations, malignancies and psychiatric disorders) among psoriatic patients with/without PsA. METHODS: All the patients on the Biobadaderm registry, a prospective inception cohort of psoriasis patients on systemic therapy, were included. Patients were divided into two groups: those with psoriasis without arthritis at the time of entry into the cohort (Pso group) and those with psoriasis and psoriatic arthritis (PsA group) at entry. Patients were followed until the censorship date (last visit in a lost-to-follow-up patient, or 10 November 2015, whichever occurred first). We excluded all the patients who developed any kind of signs and/or symptoms of joint involvement during the follow-up. A descriptive analysis was performed. We estimated incidence ratios (IRR) of adverse events during systemic treatment using a mixed-effects Poisson regression. RESULTS: We included 2120 patients: 1871 (88%) patients with psoriasis without arthritis and 249 (12%) with psoriasis and PsA. The follow-up time was 5020 patients-year in the Pso group and 762 patients-year in the PsA group. Patients with PsA had more comorbidities, particularly hypertension and liver disease; used a higher number of systemic therapies, particularly anti-TNFα drugs and combination therapy; and presented more adverse events (IRR adjusted = 1.29; 95% CI: [1.05-1.58]), particularly serious adverse events (IRR adjusted = 1.51; 95% CI: [1.01-2.26]) and infections/infestations (IRR adjusted = 1.88; 95% CI: [1.27-2.79]), independently of the associated comorbidities and present/past therapies. CONCLUSIONS: Given the differences between patients with psoriasis alone or with psoriasis associated with PsA, patients with psoriasis and PsA should be followed and managed more closely and with specific attention.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Pérez-Plaza A, Carretero G, Ferrandiz C, et al. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. J Eur Acad Dermatol Venereol. 2017. PMID: 28252811. doi:10.1111/jdv.14188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。